Effects of Tianeptine Treatment on Depression and Cognitive Function in Patients with Alzheimer's Disease: A 12-Month Retrospective Observational Study.
Alzheimer’s disease
antidepressants
dementia
depressive symptoms
tianeptine
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2022
2022
Historique:
pubmed:
14
6
2022
medline:
27
7
2022
entrez:
13
6
2022
Statut:
ppublish
Résumé
Depression is a common manifestation in Alzheimer's disease (AD). In clinical practice, antidepressant medication is often used for depression in AD. We explore the effectiveness of the atypical antidepressant tianeptine compared with other conventional antidepressants in AD patients with depression in a real-life setting. We retrospectively identified 126 AD patients who had received antidepressant treatment for 12 months with tianeptine or other antidepressants. Subjects were divided into two groups according to the treatment they had received: tianeptine group (n = 38) or other antidepressant group (n = 88). Drug effects on depression, cognition, behavior, and functional performance were evaluated at baseline, 6, and 12 months. A Mixed Effects Model Analysis was carried out to evaluate changes in performance scores. Both tianeptine and other antidepressants showed an antidepressant effect after 12 months with significant improvement on the Cornell Scale for Depression in Dementia, the Hamilton Depression Rating Scale, and the Neuropsychiatric Inventory-Depression subscale. A statistically significant improvement at 12 months was shown in the tianeptine group versus the other antidepressants group on most of the cognitive measures such as the Mini-Mental State Examination, the Letter and Category Fluency Test, the Rey Auditory Verbal Learning Test, and the Boston Naming Test. Our results suggest that tianeptine reduces depressive symptoms and improves cognition in AD patients. This could be considered clinically relevant and should inspire the design of future long-term randomized controlled trials that contribute to supporting the use of tianeptine for improving cognitive function in AD patients.
Sections du résumé
BACKGROUND
Depression is a common manifestation in Alzheimer's disease (AD). In clinical practice, antidepressant medication is often used for depression in AD.
OBJECTIVE
We explore the effectiveness of the atypical antidepressant tianeptine compared with other conventional antidepressants in AD patients with depression in a real-life setting.
METHODS
We retrospectively identified 126 AD patients who had received antidepressant treatment for 12 months with tianeptine or other antidepressants. Subjects were divided into two groups according to the treatment they had received: tianeptine group (n = 38) or other antidepressant group (n = 88). Drug effects on depression, cognition, behavior, and functional performance were evaluated at baseline, 6, and 12 months. A Mixed Effects Model Analysis was carried out to evaluate changes in performance scores.
RESULTS
Both tianeptine and other antidepressants showed an antidepressant effect after 12 months with significant improvement on the Cornell Scale for Depression in Dementia, the Hamilton Depression Rating Scale, and the Neuropsychiatric Inventory-Depression subscale. A statistically significant improvement at 12 months was shown in the tianeptine group versus the other antidepressants group on most of the cognitive measures such as the Mini-Mental State Examination, the Letter and Category Fluency Test, the Rey Auditory Verbal Learning Test, and the Boston Naming Test.
CONCLUSION
Our results suggest that tianeptine reduces depressive symptoms and improves cognition in AD patients. This could be considered clinically relevant and should inspire the design of future long-term randomized controlled trials that contribute to supporting the use of tianeptine for improving cognitive function in AD patients.
Identifiants
pubmed: 35694919
pii: JAD215630
doi: 10.3233/JAD-215630
pmc: PMC9398087
doi:
Substances chimiques
Antidepressive Agents
0
Thiazepines
0
tianeptine
0T493YFU8O
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
707-720Références
Mol Psychiatry. 2010 Mar;15(3):237-49
pubmed: 19704408
Am J Psychiatry. 2001 Jan;158(1):68-72
pubmed: 11136635
CNS Drugs. 2008;22(1):15-26
pubmed: 18072812
Eur J Pharmacol. 2007 Jun 22;565(1-3):68-75
pubmed: 17368617
Lancet. 2020 Aug 8;396(10248):413-446
pubmed: 32738937
Lancet. 2017 Dec 16;390(10113):2673-2734
pubmed: 28735855
Neurology. 1997 May;48(5 Suppl 6):S10-6
pubmed: 9153155
Am J Psychiatry. 2003 May;160(5):857-66
pubmed: 12727688
Am J Psychiatry. 2004 Jun;161(6):1096-102
pubmed: 15169699
Int Psychogeriatr. 2015 Apr;27(4):669-72
pubmed: 25412711
J Gerontol A Biol Sci Med Sci. 2003 May;58(5):M461-7
pubmed: 12730257
Am J Geriatr Psychiatry. 2005 Aug;13(8):672-85
pubmed: 16085783
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Psychiatry Clin Neurosci. 2009 Jun;63(3):374-84
pubmed: 19566770
Prog Neuropsychopharmacol Biol Psychiatry. 1998 Feb;22(2):319-29
pubmed: 9608604
Arch Gerontol Geriatr. 2011 May-Jun;52(3):264-9
pubmed: 20570375
Arch Gen Psychiatry. 2003 Jul;60(7):737-46
pubmed: 12860778
Psychiatr Danub. 2009 Jun;21(2):194-8
pubmed: 19556948
Tijdschr Gerontol Geriatr. 1991 Apr;22(2):53-9
pubmed: 2042235
J Am Geriatr Soc. 2011 Apr;59(4):577-85
pubmed: 21453380
Neurosci Behav Physiol. 2009 Jan;39(1):53-6
pubmed: 19089626
Eur Psychiatry. 2002 Jul;17 Suppl 3:331-40
pubmed: 15177089
Behav Neurosci. 1996 Dec;110(6):1321-34
pubmed: 8986335
Neuroreport. 2001 Sep 17;12(13):2971-4
pubmed: 11588613
Can J Neurol Sci. 2001 Feb;28 Suppl 1:S96-107
pubmed: 11237317
Curr Neuropharmacol. 2012 Sep;10(3):272-85
pubmed: 23450042
Neurology. 2002 Dec 10;59(11):1721-9
pubmed: 12473759
JAMA. 2002 Sep 25;288(12):1475-83
pubmed: 12243634
Nat Med. 2016 Mar;22(3):238-49
pubmed: 26937618
Int J Geriatr Psychiatry. 2005 May;20(5):471-8
pubmed: 15852433
J Clin Psychopharmacol. 2014 Apr;34(2):218-25
pubmed: 24525660
Am J Geriatr Psychiatry. 2010 Feb;18(2):136-45
pubmed: 20087081
Neuropsychobiology. 1992;25(3):140-8
pubmed: 1407480
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Lancet. 2011 Jul 30;378(9789):403-11
pubmed: 21764118
Arch Neurol. 1988 Nov;45(11):1182-6
pubmed: 3190497
Biol Psychiatry. 2000 Apr 1;47(7):586-93
pubmed: 10745050
J Psychiatr Res. 1982-1983;17(1):37-49
pubmed: 7183759
Neuropathol Appl Neurobiol. 2006 Jun;32(3):296-303
pubmed: 16640648
J Clin Psychopharmacol. 2003 Apr;23(2):155-68
pubmed: 12640217
Am J Psychiatry. 1982 Sep;139(9):1136-9
pubmed: 7114305
Am J Geriatr Psychiatry. 2010 Apr;18(4):332-40
pubmed: 20220589
Alzheimers Dement. 2015 Mar;11(3):332-84
pubmed: 25984581
J Alzheimers Dis. 2015;44(1):27-41
pubmed: 25208623
Am J Geriatr Psychiatry. 2005 Jun;13(6):441-9
pubmed: 15956263
Transl Psychiatry. 2014 Jul 15;4:e411
pubmed: 25026323
Cochrane Database Syst Rev. 2018 Aug 31;8:CD003944
pubmed: 30168578
JAMA Neurol. 2021 Nov 1;78(11):1305-1306
pubmed: 34605885
Mol Psychiatry. 2005 Jun;10(6):525-37
pubmed: 15753957
J Alzheimers Dis. 2017;58(3):725-733
pubmed: 28505970
Br J Psychiatry. 2015 Oct;207(4):293-8
pubmed: 26429684
Presse Med. 1991 Nov 14;20(37):1844-52
pubmed: 1836617
Cochrane Database Syst Rev. 2014 Jan 22;(1):CD009125
pubmed: 24449085
J Am Geriatr Soc. 2005 Dec;53(12):2083-9
pubmed: 16398891
Rev Psiquiatr Salud Ment (Engl Ed). 2019 Jul - Sep;12(3):170-186
pubmed: 30612921